Genmab to acquire ProfoundBio in $1.8bn deal to enhance cancer treatment
In a landmark move within the biotechnology sector, Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have announced a definitive agreement under which Genmab will acquire ProfoundBio for a staggering USD 1.8 billion in cash. This all-cash transaction underscores Genmab’s strategic intent to broaden its clinical pipeline and enhance its technological capabilities in the fight against […]